What is known and objective: Neurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian-informed clearance estimates supported a therapeutic intervention for acyclovir-associated neurotoxicity.
Summary
What is known and objective: Neurotoxicity is a side effect of acyclovir. We report the first case, to our knowledge, whereby Bayesian-informed clearance estimates supported a therapeutic intervention for acyclovir-associated neurotoxicity.
Case summary:
A 62-year-old male with the diagnosis of disseminated zoster was being treated with intravenous (IV) acyclovir when he developed symptoms of acute neurotoxicity. Acyclovir had been dose-adjusted for renal dysfunction according to traditional creatinine clearance estimates; however, as the patient was also on vancomycin, Bayesian estimates of vancomycin clearances were performed, which revealed a 2-fold lower creatinine clearance. In response to the Bayesian estimates, acyclovir was discontinued, and improvements in mentation were noted within 24 hours.
What is new and conclusion: Alternate approaches to estimate renal function beyond
Cockcroft-Gault, such as a Bayesian approach used in our patient, should be considered when population estimates are likely to be inaccurate and potentially dangerous to the patient.
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| WHAT IS KNOWN AND OBJECTIVE
Acyclovir is highly efficacious in the treatment and prophylaxis of varicella zoster and herpes simplex viral infections. Accumulation of acyclovir 1 and valacyclovir 2 has been associated with neurotoxocity, manifesting as worsening of mental status, in some cases hallucinations, agitation or lethargy. 1, 3 Most reports that describe acyclovirassociated neurotoxicity coincide with renal dysfunction in the affected patient, as acyclovir is eliminated primarily through excretion in the urine. 4, 5 Renal dysfunction appears to be a strong predictor of acyclovir-associated neurotoxicity. However, the exact exposuretoxicity relationship for acyclovir-associated neurotoxicity has not been well defined. [6] [7] [8] Previous studies have identified a relationship between acyclovir exposure and neurotoxicity. Case reports indicate that acyclovir-induced neurotoxicity can manifest within 1-2 days after patients' experience of supra-normal acyclovir concentrations, and sometimes as early as within a few hours after a single dose. Other cases failed to demonstrate a clear relationship between acyclovir exposure and toxicity. 4, 9 Given the timeframe of toxicity from these studies, peak blood concentrations (ie, Cmax) or average daily drug exposure (as measured by the area under the concentration-time curve;
ie, AUC) may predict the onset of neurotoxicity.
As acyclovir clearance is closely related to creatinine clearance, changes in renal function must be closely monitored during acyclovir therapy in order to avoid potentially neurotoxic accumulation of the parent drug or its metabolites. Several studies have shown that as renal function declines, a larger proportion of the parent drug is converted to the 9-carboxymethoxymethylguanine (CMMG) metabolite. Likewise, increased peripheral plasma acyclovir concentrations have been associated with increased exposure to both CMMG and the parent drug in the CNS. 
| DETAILS OF CASE
Clinical data (eg, drug administration, microbiology reports, clinical chemistry) were obtained from the electronic medical record. A case report exemption was obtained from the Northwestern University Institutional Review Board.
A 62-year-old Caucasian male presented to an outside facility with complaints of diarrhoea, poor oral intake, and weight loss. The patient's past medical history was significant for a history of Goodpasture syndrome complicated by end-stage renal disease requiring a living donor kidney transplant eleven years prior to presentation, chronic allograft glomerulopathy, and a recent diagnosis of collagenous colitis. Prior to admission to the outside facility, the patient had received a fourteenday course of oral valacyclovir for presumed dermatologic VZV reactivation; however, he was not experiencing neurotoxic symptoms at that time. Physical examination findings at the outside facility were concerning for evolving lesions, and the patient was started on intravenous (IV) acyclovir two days prior to transfer. Mental status changes from baseline and confusion were noted within 48 hours following initiation of IV acyclovir. The patient was subsequently transferred to our facility for further evaluation and management.
Upon transfer to our facility, examination was notable for hypovolaemia and altered mental status (eg, oriented to person and city, but not date, state, or situation). Actively draining, vesicular skin lesions were identified diffusely throughout the patient's cervical, thoracic, and lumbar back, with additional erythematous, encrusted lesions on his abdomen. Neurologic examination was notable for asterixis and brisk reflexes. Serum creatinine was 2.5 mg/dL (baseline of 1.8 mg/dL).
Despite recent weight loss, the patient maintained a body mass index Brudzinski's signs were negative. Further, there were active rash lesions overlaying the lumbar spine. Thus, the procedure was initially deferred.
On hospital day +3, two sets of blood cultures turned positive and a Gram stain revealed Gram-positive cocci. The patient was empirically initiated on vancomycin IV (dosed at 15 mg/kg every 18 hours). That same day, the patient's mental status notably declined. On hospital day +4, the patient was disoriented and had waxing and waning mental status. On hospital day +5, the patient was found to have a flat affect and was minimally responsive except to loud or painful stimuli. On hospital day +6, the patient was non-verbal and somnolent. In response to the patient's declining mental status, a lumbar puncture was performed on day +5. The cerebrospinal fluid (CSF) examination revealed 37 white cells with lymphocytic predominance, and a VZV polymerase chain reaction amplification test on CSF fluid revealed 912 copies/mL of VZV (Table 1 ).
In the light of the clinical and positive virologic findings and progressively worsening mental status, viral encephalitis could not be excluded at the time. However, in the setting of therapeutic doses of acyclovir and Bayesian predictions of poor renal function, we maintained a higher clinical suspicion for acyclovir toxicity over inadequately treated VZV encephalitis. Therefore, on day +6, our team recommended temporary discontinuation of the IV acyclovir, and further doses were held.
On day +7, the patient was observed to have marked improvement in mental status including increased responsiveness, improved dysarthria and appropriate behaviour. After the patient's mentation improved, he recalled visual hallucinations in the previous days, specifically red coloration of room and walls. By hospital day +11, mental status returned to baseline. Valacyclovir was ultimately resumed to complete a 21-day course of valacyclovir (dose-adjusted to 1000 mg twice daily) for possible meningoencephalitis and dermatomal VZV, during which mentation remained stable. Over this period, the previous Gram-positive cocci were ultimately identified to be Staphylococcus aureus. Echocardiography was consistent with mitral valve endocarditis, prompting a 6-week course of vancomycin therapy.
| Traditional and Bayesian estimates of renal clearance and resolution of altered mental status
Our recommendation to cease acyclovir dosing was based on our suspicion that the serum creatinine and Cockcroft-Gault 14 calculated
creatinine clearance ( . Distribution volume was scaled to total body weight. Of the 18 sets of pharmacokinetic parameters in the final model joint probability distribution, the Bayesian software identified the set of parameters that minimized the average weighted squared error between the observed and predicted vancomycin concentrations.
The patient had received three doses of vancomycin at the time of the assessment. Three sequential vancomycin serum concentrations were obtained after the third dose. The vancomycin elimination rate constant (K el ) was calculated from the three sequential concentrations using traditional pharmacokinetic formulae (Table 2) . [21] [22] [23] Our patient experienced many of the symptoms temporally associated with high-dose acyclovir. The rapid resolution of our patient's symptoms after acyclovir discontinuation supports a causal effect (Naranjo score =5, probable association) whereas progressive VZV encephalitis was less likely the cause of his acute episode of neurologic dysfunction. In conclusion, acyclovir-associated neurotoxicity was detected in a patient for whom Cockcroft-Gault estimates of renal function poorly predicted vancomycin clearance. Vancomycin clearance was calculated using traditional and Bayesian approaches as a clinical estimate of acyclovir clearance. Using the Bayesian estimated clearance, a modified drug-dosing regimen was applied after abatement of the patient's neurotoxic symptoms. As true renal function may not correlate with renal function estimates, alternate approaches to estimate renal function beyond Cockcroft-Gault, such as the Bayesian approach used in our patient, may be necessary to minimize the likelihood of toxicity.
| WHAT IS NEW AND CONCLUSION

